XBL Enhances Key Services and Expands With New Laboratory in China

PLAINSBORO, N.J., May 19, 2009 (GLOBE NEWSWIRE) -- XenoBiotic Laboratories
(XBL) continues to enhance its core services in the bioanalytical and ADME
areas with the addition of a large molecule bioassay/cell-based assay group,
Debra LIMS, QWBA and in-house NMR services. In addition, in summer 2009,
XBL-China will open its doors. 

"For over 21 years, XBL has established itself as a premiere contract
laboratory providing metabolism and bioanalytical services to the
pharmaceutical and agrochemical industries. With the addition of a
state-of-the-art laboratory and expertise to conduct Quantitative Whole Body
Autoradiography (QWBA) studies, in-house NMR (500 MHz) and the industry
standard Debra LIMS software, we now offer a complete and comprehensive package
of services for Absorption, Distribution, Metabolism and Excretion (ADME)
studies," according to Dennis Heller, Vice President of Pharmaceutical
Development. "In addition, we recognized the expanding need for quantitative
bioanalytical services for biologics (biotherapeutics and biomarkers) and, as a
result, invested in a new biologics group that will provide ELISA-based
services for quantitative PK bioanalysis for biotherapeutics, immunogenicity
screening and biomarker assays. Our biologics group is also developing key
cell-based assays to screen the biological activity of macromolecules." 

XBL-China's new 36,000 sq.ft laboratory in Nanjing has a 12,000 sq.ft vivarium
and top of the line analytical instrumentation. With additional offices in
Shanghai, XBL-China will provide bioanalytical and metabolism services to the
exacting standards of XBL's New Jersey facility. According to Jinn Wu,
President and Chief Executive Officer, "The initial goal for XBL-China is to
offer GLP-level bioanalytical as well as discovery PK services to support drug
development programs being conducted in Asian countries. Additional services
such as synthetic chemistry, formulation services, Phase I clinical trial
conduct, and SFDA registration are planned for the future. This is a
significant expansion for XBL and will allow us to provide services to global
pharmaceutical companies. An open house ceremony is planned for October 2009." 

About XBL. XenoBiotic Laboratories, Inc. (XBL) is a leading contract laboratory
known for high quality science and project management, specializing in
providing bioanalytical and metabolism services to the pharmaceutical, biotech,
and agrochemical industries. Bioanalytical services are offered for small
molecule and biologic (protein/peptide) drugs including method development/
validation and sample analysis in support of pre-clinical (GLP) and clinical
studies. Metabolism services include a comprehensive set of preclinical
radiolabel ADME, in vitro metabolism, CYP p450, and protein binding studies.
XBL is FDA and EPA inspected, AAALAC accredited, and NRC, DEA, and USDA
licensed. XBL. Invested in science. Invested in your success. 

Visit www.XBL.com for more information about XBL. 

The XenoBiotic Laboratories, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6194 

CONTACT:  XenoBiotic Laboratories, Inc. 
          Dennis Heller
          609-799-2295
          dheller@xbl.com